- Sort by:
- Browse by:
- Permission not
granted for presentation
CAR therapy beyond the CD19 paradigm
Michel Sadelain
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- podium video
- audio only
- Audio only
Improving remission durability after CAR T cell therapy for ALL
Terry J Fry
National Cancer Institute, Bethesda, MD, United States
- Permission not
granted for presentation
Title to be announced
Martin Pule
Autolus, London, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Engineering human T cells with non-viral genome targeting
Theodore Roth
University of California, San Francisco, CA, United States
- Permission not
granted for presentation
PROTAC-mediated protein degradation: A chemical equivalent of CRISPR
Craig M. Crews
Yale Univ., New Haven, CT, United States
- Free
- slides video
- audio + slides
- All slides included
Block the exits: ABL001 enables dual targeting of BCR-ABL
Andrew Wylie
Novartis, Cambridge, MA, United States
- Free
- Coming soon
- Some slides withheld
Targeted inhibition of the ERK pathway: Precision medicine?
Neal Rosen
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Permission not
granted for presentation
Title to be announced
Jeffrey A. Engelman
Novartis, Cambridge, MA, United States